Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. - Wikidata - awgldk - TriplyDB

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

http://www.wikidata.org/entity/Q50506114

about

Functional capacity: a new framework for the assessment of everyday functioning in schizophrenia Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update Autophagy has a key role in the pathophysiology of schizophrenia Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives.Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies.The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery Participants with schizophrenia retain the information necessary for informed consent during clinical trials.New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model Neuropsychological profile in adult schizophrenia measured with the CMINDS Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers The association of cardiac vagal control and executive functioning--findings from the MIDUS study A quantitative system pharmacology computer model for cognitive deficits in schizophrenia Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.Newer antipsychotics and upcoming molecules for schizophrenia.Notch signalling in adult neurons: a potential target for microtubule stabilization.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.Placebo Response and Practice Effects in Schizophrenia Cognition Trials.ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits.Increased Stability of Microtubules in Cultured Olfactory Neuroepithelial Cells from Individuals with Schizophrenia.Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders.Validation of a Computerized test of Functional Capacity.ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease.

P2860

Q26786322-615F8D1F-88EB-4FB7-9428-53206C786372 Q26864324-8DEE9686-6A48-409E-BE8D-33A1FC28C21F Q26865358-D811F3D6-1272-4217-9933-E635450A00AF Q28299995-808607B9-2205-498F-ABB1-58222D046CCC Q28304604-31D01F81-59FC-48D1-9E9F-9E4D16B0974B Q30439296-DFE44184-81F7-4C9A-8072-DCEDEACBB9F0 Q30536299-C56A4985-2C23-4781-BBDD-533952B95046 Q30663071-9165EA0B-ED40-4A1B-B980-F1B81F35ACB5 Q33620592-0B0BAA52-0536-440C-A55E-A61804CD46E7 Q33705188-899609D1-654C-42DD-9635-E70766FFA0EB Q34644263-F64F3A3C-FCBF-43DB-AF5E-A57DFF5C3EDA Q35209222-631DB74A-B84A-4345-BE6F-58AF6DF1FDA9 Q35579200-AA9CBC2C-1C4C-412A-831F-5381FE23A67A Q35653810-71F559EE-47BB-4DA1-A8A5-4B96355A7A00 Q35739009-AEAB0B3B-FE87-40E6-A45C-0D0D6316C1B8 Q35750003-672DB49A-60D7-460F-BC72-65EE853E7BEA Q35785918-CF8C2889-1CE3-4898-B678-C18C3E8F4BEB Q35852866-F8FD2826-6FD2-42C0-8194-06F206656AE2 Q36265934-217CEFF8-A47C-465B-851F-719A593622C8 Q36408176-CDD85F7D-CABF-4E88-8354-DF40D2CF12A6 Q36460048-7196346C-789C-4B00-8F27-57DCA2B6ACD1 Q36673648-2B21DB61-90AC-4FEF-8BA9-EFA67EE6C995 Q36795559-EF7C44F6-4533-4B18-8C73-C8D66DAD940E Q36850555-203FF5A8-CEEE-4000-946D-8F4BAEFD4277 Q36935148-4BF8B164-808F-4BA8-8DD5-7C0C21E9BD64 Q37256805-600F0A9F-ECCB-4B92-82C6-CF7B0E21F5DD Q37986036-C920607E-1639-4BFE-90B8-7CD2A9D3C8DD Q38094930-11D6C18D-FA3A-48D2-871A-712FCB9E5E28 Q38162441-D25541EB-0037-4727-821E-113FE6E6D2B8 Q38187948-5F769F15-5302-40D4-94BB-95032B331353 Q38209914-B486650A-B5B8-4B14-8504-38FE11756F31 Q38636792-96BF8DB6-7689-44CC-8DA1-A46EB49EDA8B Q38715567-DF80261F-E77E-48AB-9B82-6ED7B0177761 Q38766657-3C57B03C-8DC8-4158-9D4C-674F7FC624FD Q38792682-3FBC6126-860E-45E2-AE53-BF9E38D2EC6E Q38808332-74C2B0F0-B81C-4244-A0B2-16D4B24684F9 Q38960118-A59AF190-59B7-4859-88CC-E6FBC041DD3B Q41573058-E8EC36FD-81EA-4CE1-BB2F-1B92778868D4 Q42121970-46717DD1-CDD8-4734-B0FE-51F27615E0D4 Q47756433-866A2193-AA7E-49D4-A2AC-626ED7C82540

P2860

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

http://www.wikidata.org/entity/Q50506114

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Effect of the neuroprotective ...... nal capacity in schizophrenia.

@en

Effect of the neuroprotective peptide davunetide

@nl

type

label

Effect of the neuroprotective ...... nal capacity in schizophrenia.

@en

Effect of the neuroprotective peptide davunetide

@nl

prefLabel

Effect of the neuroprotective ...... nal capacity in schizophrenia.

@en

Effect of the neuroprotective peptide davunetide

@nl

P1433

Q50506114-A319D83B-2A17-4DFC-8995-6329FE8D1552

P1476

Q50506114-428AE555-3616-488F-823D-7973B1E7C3A6

P2093

Q50506114-229FB9E7-C4F8-4E29-A10E-C54A683407F2

Q50506114-457ABC0C-0BC3-4BCA-B072-8B61DEF8EED3

Q50506114-487A3142-0A4D-442A-806E-7F327FCD1A74

Q50506114-4A32D866-C167-449B-9D93-DEDF2E016B08

Q50506114-5070C662-021C-49EF-923A-E7E6DBB9D487

Q50506114-5357CF1D-2A4E-4AA5-BAED-DD64A2E28822

Q50506114-5A66C6BE-2F6C-4B19-95AB-B291906340D2

Q50506114-6C885822-D17D-4311-90A1-EB53E28EC1E3

Q50506114-A3E18E6F-89FA-42BB-B6EE-63AA93FC1C6B

Q50506114-A42A0E44-E454-45C1-85CE-12AE0C657F0D

P304

Q50506114-F4F77BAD-721E-4F2B-9DA1-1B5F7539B27E

P31

Q50506114-FF545944-57F1-4B38-BB25-9D1AC6CBB990

P356

Q50506114-1ECA2284-6D66-455C-AE3D-F7F15E95E80F

P407

Q50506114-0280B5FE-418C-4A62-A0FD-F0F550EC41F1

P433

Q50506114-63A0DD2A-61D6-403E-B117-ABA1E4E24F73

P478

Q50506114-DEA0A4AE-0438-4ABA-9404-A7977ABD43A8

P50

Q50506114-47CAA270-50AB-47E4-AC9E-1AF849B0A1D1

Q50506114-B0309559-FF86-4FBA-B6E9-16E0125807C2

Q50506114-C1D40E90-F466-4CEC-9054-9034336E0888

Q50506114-DAFDAAE8-1B7A-4DAD-9C1A-18EE2D390898

Q50506114-E70D2E8C-696B-42BD-9E8E-6E9EDA500F98

P577

Q50506114-8137C01E-FB91-4604-8433-E2FA91A5A6D0

P5875

Q50506114-EBF375F7-1368-42C1-9872-F42B06E8E8A6

P698

Q50506114-C233F618-D47C-47ED-BD40-7C1F24A16999

P921

Q50506114-995F9062-C4CF-455A-9E29-0B7719AE544B

P356

J.SCHRES.2011.11.001

P1433

Schizophrenia Research

P1476

Effect of the neuroprotective ...... nal capacity in schizophrenia.

@en

P2093

Deanna S Barch

http://www.w3.org/2001/XMLSchema#string

Fred Jarskog

http://www.w3.org/2001/XMLSchema#string

James M Gold

http://www.w3.org/2001/XMLSchema#string

James Robinson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Lieberman

http://www.w3.org/2001/XMLSchema#string

John G Csernansky

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Karen S Nolan

http://www.w3.org/2001/XMLSchema#string

M Patricia Ball

http://www.w3.org/2001/XMLSchema#string

Richard S E Keefe

http://www.w3.org/2001/XMLSchema#string

P304

25-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SCHRES.2011.11.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Daniel C Javitt

Michael Foster Green

Larry J Seidman

P577

2011-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51878072

http://www.w3.org/2001/XMLSchema#string

P698

22169248

http://www.w3.org/2001/XMLSchema#string

P921